Sep 27 2022

Halberd Enters Strategic Alliance for Longevity, Alzheimer’s Disease, and Cancer Early Detection, Prevention and Treatment

By |2022-09-26T21:24:04-04:00September 27th, 2022|Featured, Investor News, News, Press Releases|0 Comments

Jackson Center, PA, September 27, 2022 – Halberd Corporation (OTC-PINK: "HALB”) entered into a strategic alliance with AI Longevity, Inc. and Stem of Hope to form a strategic alliance as a wholly owned subsidiary of Halberd Corporation named “ExtendalifeTM”.  The mission will be to develop treatments intended to increase longevity and develop successful Alzheimer’s Disease ...

Aug 23 2022

Halberd Demonstrates Precise Control of Key Cancer Related T-Cell Protein

By |2022-08-22T20:05:56-04:00August 23rd, 2022|Investor News, Medical, News, Press Releases|0 Comments

Jackson Center, PA, August 23, 2022 – Halberd Corporation (OTC-PINK: "HALB”) researchers have demonstrated the ability to precisely control the level of PD-1 in human blood serum in laboratory in-vitro testing.  PD-1 (programmed cell death–1) is a T-Cell protein which can be used by tumor cells to fool the body’s immune system into allowing the ...

Jul 20 2022

Halberd Corp. Launches “Halberd Cancer Therapeutics, LTD” Wholly Owned Subsidiary

By |2022-07-19T20:21:05-04:00July 20th, 2022|Featured, Investor News, News|0 Comments

Jackson Center, PA, July 20, 2022 – Halberd Corporation (OTC-PINK: "HALB”) announced the formation of Halberd Cancer Therapeutics, LTD, as a wholly owned subsidiary.  Halberd’s patented extracorporeal technology has demonstrated the capacity for successful application to a wide variety of diseases and health-related illnesses.  For now, the new entity will be staffed by Halberd personnel ...

Jul 12 2022

Halberd Corporation Update, CEO Letter and 2022 Expectations

By |2022-07-11T19:19:34-04:00July 12th, 2022|Featured, Investor News, News, Press Releases|0 Comments

Q2 Accomplishments and a Look to the Future Jackson Center, PA, July 12, 2022.  Halberd Corporation (OTC: HALB) This past quarter has witnessed some very significant technical and organizational achievements by the Halberd team.  The accomplishments for the Second Quarter ending June 30, 2022, are as follows: 2Q ACHIEVEMENTS Added an animal testing expert (DVM/PhD) ...

Jun 21 2022

Halberd Creates Subsidiary to Apply Its Patented Technology to Treat Cancer

By |2022-06-21T05:23:46-04:00June 21st, 2022|Featured, Investor News, News|0 Comments

Recognizing the breadth of application of its patented extracorporeal treatment approach, Halberd Corporation (OTC-PINK: "HALB”) announced the creation of a subgroup of researchers to focus on cancer treatment.  Halberd’s technology is capable of being applied to many diseases, and management decided to not delay the development of potential cancer treatments. The subgroup will be guided ...

May 12 2022

Halberd Submits Audited Financials; Files Form-10 as First Step to Up-list to OTCQB

By |2022-05-11T18:58:14-04:00May 12th, 2022|Investor News, News, Press Releases|0 Comments

Jackson Center, PA, May 12, 2022 – Halberd Corporation (OTC-PINK: "HALB”) submitted its fully audited financials through its fiscal second quarter and Form-10 to the SEC as its initial step to up-list from OTC-PINK to OTCQB on the OTC Markets exchange.  Once Halberd’s shares are qualified under the Securities Exchange Act of 1934 (the “34 ...

Oct 25 2021

Halberd Files Provisional Patent on Breakthrough Obesity Treatment

By |2021-10-24T19:32:33-04:00October 25th, 2021|Featured, Investor News, Medical, News|0 Comments

Jackson Center, PA, October 25, 2021 – Halberd Corporation (OTC-PINK: HALB) announces the filing of a provisional patent application with the US Patent and Trademark Office covering their extracorporeal removal from the blood of patients of the various proteins, cytokines and antigens associated with obesity.  Removal of these obesity-related target elements would reduce or eliminate ...

Oct 20 2021

Halberd’s PTSD/Alzheimer’s R&D Reveals Link to Potential Obesity Cure

By |2021-10-19T21:30:49-04:00October 20th, 2021|Featured, Investor News, Medical, News|0 Comments

Jackson Center, PA, October 20, 2021 – Halberd Corporation’s (OTC-PINK: HALB) ongoing research into discovering treatments/cures for PTSD, Alzheimer’s Disease, and other neurodegenerative diseases has led to a potential breakthrough in the battle against obesity.  Research has indicated inflammatory cytokines present in the Cerebral Spinal Fluid (CSF) of neurodegenerative disease patients are also found in ...

Oct 12 2021

Halberd and GTX Corp Sign Scientific Collaboration and Reseller Agreement

By |2021-10-11T21:52:59-04:00October 12th, 2021|Featured, Investor News, News|0 Comments

GTX and Halberd will begin collaborating on developing and testing treatments for Alzheimer’s Disease/PTSD and other neurological diseases and GTX will begin marketing Halberd’s VitaShieldMaxTM Immune Support through their online ecommerce platform. Jackson Center, PA, October 12, 2021 – Halberd Corporation (OTC-PINK: HALB) and GTX Corp (OTC-PINK: GTXO) have agreed to work together on various ...

Oct 7 2021

Halberd Corporation CEO Letter

By |2021-10-04T21:24:09-04:00October 7th, 2021|Featured, Investor News, News|0 Comments

Q3-21 Accomplishments and Q4 Plans Jackson Center, PA, October 7, 2021 Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC-PINK: HALB) This past quarter, Halberd has made some very significant and unparalleled achievements developing treatments for neurodegenerative diseases, such as PTSD/ CTE (Post Traumatic Stress Disorder/Chronic Traumatic Encephalopathy), Alzheimer’s Disease, Parkinson’s Disease, etc. As ...

Go to Top